BCR and lymphoma: The BCR of lymphoma cells represents an ideal target for new therapeutic approaches and different BCR‐targeting therapeutic formats like anti‐idiotype antibodies and peptibodies have been developed with moderate clinical success [18, 19, 20, 21, 22, 23].